Evidence map›Paper›PMID 29334307›Full record

ArticleCell cycle (Georgetown, Tex.)2018

Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model.

Kentaro Miyake, Kei Kawaguchi, Tasuku Kiyuna, Masuyo Miyake, Kentaro Igarashi, Zhiying Zhang, Takashi Murakami, Yunfeng Li, Scott D Nelson, Irmina Elliott and 9 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Kentaro Miyakea AntiCancer Inc. , San Diego , CA.ORCID 0000-0002-4680-4317
Kei Kawaguchia AntiCancer Inc. , San Diego , CA.
Tasuku Kiyunaa AntiCancer Inc. , San Diego , CA.
Masuyo Miyakea AntiCancer Inc. , San Diego , CA.
Kentaro Igarashia AntiCancer Inc. , San Diego , CA.
Zhiying Zhanga AntiCancer Inc. , San Diego , CA.
Takashi Murakamia AntiCancer Inc. , San Diego , CA.
Yunfeng Lie Deparment of Pathology , University of California , Los Angeles , CA.
Scott D Nelsone Deparment of Pathology , University of California , Los Angeles , CA.
Irmina Elliottf Division of Surgical Oncology , University of California , Los Angeles , CA.
Tara Russellf Division of Surgical Oncology , University of California , Los Angeles , CA.ORCID 0000-0002-3912-3601
Arun Singhd Division of Hematology-Oncology , University of California , Los Angeles , CA.
Yukihiko Hiroshimac Department of Gastroenterological Surgery , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
Masashi Momiyamac Department of Gastroenterological Surgery , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
Ryusei Matsuyamac Department of Gastroenterological Surgery , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
Takashi Chishimac Department of Gastroenterological Surgery , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
Itaru Endoc Department of Gastroenterological Surgery , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
Fritz C Eilberf Division of Surgical Oncology , University of California , Los Angeles , CA.ORCID 0000-0003-3336-9333
Robert M Hoffmana AntiCancer Inc. , San Diego , CA.
University of California San Diego · USUniversity of California, Los Angeles · USYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit is a rare type of sarcoma. The aim of this study was to determine drug sensitivity for a regionally-recurrent case of GIST using a patient-derived orthotopic xenograft (PDOX) model. The PDOX model was established in the anterior wall of the stomach. GIST PDOX models were randomized into 5 groups of 6 mice each when the tumor volume reached 60 mm

Indexed as

AnimalsAntineoplastic AgentsBody WeightDisease Models, AnimalDrug Resistance, NeoplasmExonsGastrointestinal Stromal TumorsHumansImatinib MesylateMaleMiceMice, NudeMutationNeoplasm Recurrence, LocalPhenylurea CompoundsProto-Oncogene Proteins c-kitAntineoplastic AgentsImatinib MesylatePhenylurea CompoundsProto-Oncogene Proteins c-kitPyridinesregorafenibGISTGleevecimatinibnude micepatient-derived orthotopic xenograftregorafenib

Identifiers

PMID29334307
PMCPMC5969563
OpenAlexW2783765336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.